Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma

Analysis of web-based data from the Korean Lymphoma Working Party Registry

Hyeon Gyu Yi, Jinseok Kim, Cheolwon Suh, Won Seog Kim, Jae Yong Kwak, Jong Seok Lee, Yang Soo Kim, Young Don Joo, Yoo Hong Min, Hong Ghi Lee, Sung Soo Yoon, Jong Ho Won, Seonyang Park, Hugh Chul Kim, Chul Soo Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. Methods: In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. Results: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low-and low-intermediate-risk groups according to IPI scores significantly increased survival duration. Conclusion: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalBlood Research
Volume48
Issue number2
DOIs
Publication statusPublished - 2013 Sep 23

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Registries
Lymphoma
Survival
Epidemiology
Lost to Follow-Up
Vincristine
Korea
Prednisone
Doxorubicin
Cyclophosphamide
Radiation
Therapeutics
Rituximab

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Yi, Hyeon Gyu ; Kim, Jinseok ; Suh, Cheolwon ; Kim, Won Seog ; Kwak, Jae Yong ; Lee, Jong Seok ; Kim, Yang Soo ; Joo, Young Don ; Min, Yoo Hong ; Lee, Hong Ghi ; Yoon, Sung Soo ; Won, Jong Ho ; Park, Seonyang ; Kim, Hugh Chul ; Kim, Chul Soo. / Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma : Analysis of web-based data from the Korean Lymphoma Working Party Registry. In: Blood Research. 2013 ; Vol. 48, No. 2. pp. 115-120.
@article{f2543e98d46343b385d45faeca4405d8,
title = "Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: Analysis of web-based data from the Korean Lymphoma Working Party Registry",
abstract = "Background: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. Methods: In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. Results: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53{\%} vs. 47{\%}). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9{\%}) were alive, with 80{\%} free of disease, 417 were dead (26.8{\%}), with 13{\%} free of disease, and 144 (9.3{\%}) were lost to follow-up, with 23{\%} free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low-and low-intermediate-risk groups according to IPI scores significantly increased survival duration. Conclusion: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.",
author = "Yi, {Hyeon Gyu} and Jinseok Kim and Cheolwon Suh and Kim, {Won Seog} and Kwak, {Jae Yong} and Lee, {Jong Seok} and Kim, {Yang Soo} and Joo, {Young Don} and Min, {Yoo Hong} and Lee, {Hong Ghi} and Yoon, {Sung Soo} and Won, {Jong Ho} and Seonyang Park and Kim, {Hugh Chul} and Kim, {Chul Soo}",
year = "2013",
month = "9",
day = "23",
doi = "10.5045/br.2013.48.2.115",
language = "English",
volume = "48",
pages = "115--120",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "2",

}

Yi, HG, Kim, J, Suh, C, Kim, WS, Kwak, JY, Lee, JS, Kim, YS, Joo, YD, Min, YH, Lee, HG, Yoon, SS, Won, JH, Park, S, Kim, HC & Kim, CS 2013, 'Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: Analysis of web-based data from the Korean Lymphoma Working Party Registry', Blood Research, vol. 48, no. 2, pp. 115-120. https://doi.org/10.5045/br.2013.48.2.115

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma : Analysis of web-based data from the Korean Lymphoma Working Party Registry. / Yi, Hyeon Gyu; Kim, Jinseok; Suh, Cheolwon; Kim, Won Seog; Kwak, Jae Yong; Lee, Jong Seok; Kim, Yang Soo; Joo, Young Don; Min, Yoo Hong; Lee, Hong Ghi; Yoon, Sung Soo; Won, Jong Ho; Park, Seonyang; Kim, Hugh Chul; Kim, Chul Soo.

In: Blood Research, Vol. 48, No. 2, 23.09.2013, p. 115-120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma

T2 - Analysis of web-based data from the Korean Lymphoma Working Party Registry

AU - Yi, Hyeon Gyu

AU - Kim, Jinseok

AU - Suh, Cheolwon

AU - Kim, Won Seog

AU - Kwak, Jae Yong

AU - Lee, Jong Seok

AU - Kim, Yang Soo

AU - Joo, Young Don

AU - Min, Yoo Hong

AU - Lee, Hong Ghi

AU - Yoon, Sung Soo

AU - Won, Jong Ho

AU - Park, Seonyang

AU - Kim, Hugh Chul

AU - Kim, Chul Soo

PY - 2013/9/23

Y1 - 2013/9/23

N2 - Background: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. Methods: In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. Results: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low-and low-intermediate-risk groups according to IPI scores significantly increased survival duration. Conclusion: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

AB - Background: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. Methods: In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. Results: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low-and low-intermediate-risk groups according to IPI scores significantly increased survival duration. Conclusion: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

UR - http://www.scopus.com/inward/record.url?scp=84884247579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884247579&partnerID=8YFLogxK

U2 - 10.5045/br.2013.48.2.115

DO - 10.5045/br.2013.48.2.115

M3 - Article

VL - 48

SP - 115

EP - 120

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 2

ER -